Study of INCB053914 in Subjects With Advanced Malignancies | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02587598

Study of INCB053914 in Subjects With Advanced Malignancies
For more details on this clinical trial, including contact information, please see this trial’s listing on

This is an open-label, dose-escalation study of the PIM kinase inhibitor INCB053914 in subjects with advanced malignancies. The study will be conducted in 2 parts. Part 1 (dose escalation) will evaluate safety, and determine the maximum tolerated dose of INCB053914 and the recommended phase 2 dose (a tolerated pharmacologically active dose that will be taken forward into Part 2 of the study). . Part 2 (dose expansion) will further evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of the recommended Phase 2 dose.

Study Date: 
Thu, 10/01/2015 to Sun, 10/01/2017
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Drug: INCB053914 Initial cohort dose of INCB053914 at the protocol-specified starting dose in three treatment groups in dose escalation, with subsequent cohort escalations in the four treatment groups based on protocol-specific criteria. INCB053914 tablets to be administered by mouth.